for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Ra Pharmaceuticals Inc

RARX.OQ

Latest Trade

25.87USD

Change

0.31(+1.21%)

Volume

138,424

Today's Range

25.43

 - 

26.17

52 Week Range

11.35

 - 

36.92

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
25.56
Open
25.56
Volume
138,424
3M AVG Volume
10.87
Today's High
26.17
Today's Low
25.43
52 Week High
36.92
52 Week Low
11.35
Shares Out (MIL)
47.01
Market Cap (MIL)
1,201.69
Forward P/E
-12.85
Dividend (Yield %)
--

Latest Developments

More

Ra Pharma Receives Orphan Drug Designation From The U.S. FDA For Zilucoplan For The Treatment Of Myasthenia Gravis

Ra Pharmaceuticals Earns Clinical Development Milestone For Oral Macrocyclic Peptide Candidate

Ra Pharmaceuticals Reports Second Quarter 2019 Financial Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Ra Pharmaceuticals Inc

Ra Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system. It is developing its lead product candidate, RA101495, a self-administered subcutaneous (SC) injection. RA101495 is injected into the tissue under the skin for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). The Company is also developing RA101495 to treat other debilitating complement-mediated diseases such as generalized myasthenia gravis (gMG) and lupus nephritis (LN). It also focuses on discovery and preclinical programs targeting selective inhibition of other uncontrolled complement pathway factors to treat a variety of ophthalmic, renal and inflammatory diseases. The Company uses its Extreme Diversity platform, macrocyclic peptide chemistry technology which produces synthetic macrocyclic peptides.

Industry

Biotechnology & Drugs

Contact Info

87 Cambridgepark Dr

+1.617.4014060

http://rapharma.com/

Executive Leadership

Edward T. Mathers

Independent Chairman of the Board

Douglas A. Treco

President, Chief Executive Officer, Co-Founder, Director

David Charles Lubner

Chief Financial Officer, Executive Vice President

Simon Read

Chief Scientific Officer

Ramin Farzaneh-Far

Chief Medical Officer

Key Stats

1.60 mean rating - 10 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-6.980

2017

-2.410

2018

-2.060

2019(E)

-1.989
Price To Earnings (TTM)
--
Price To Sales (TTM)
480.68
Price To Book (MRQ)
6.24
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-53.63
Return on Equity (TTM)
-49.96

Latest News

BRIEF-Ra Pharma - Entered Sales Agreement With Stifel Pursuant To Which Co May Sell, Up To $50 Mln Of Shares Of Common Stock

* RA PHARMA - ENTERED SALES AGREEMENT WITH STIFEL PURSUANT TO WHICH CO MAY SELL, UP TO $50 MILLION OF SHARES OF COMMON STOCK, THROUGH STIFEL AS SALES AGENT Source text: (https://bit.ly/2G0vejI) Further company coverage:

BRIEF-Ra Pharmaceuticals Q1 Loss Per Share $0.61

* RA PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ra Pharmaceuticals Announces Presentation Of RA101495 SC Phase 2 gMG Clinical Trial Design At 70Th Annual AAN Meeting

* RA PHARMACEUTICALS ANNOUNCES PRESENTATION OF RA101495 SC PHASE 2 GMG CLINICAL TRIAL DESIGN AT THE 70TH ANNUAL AAN MEETING

BRIEF-Ra Pharmaceuticals Reports Q4 Loss Per Share $0.67

* RA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

BRIEF-Ra Pharmaceuticals Says Public Offering Of 8.40 Mln Common Shares Priced At $6.00/Share

* RA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ra Pharmaceuticals Announces Proposed Public Offering Of Common Stock

* RA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 1B Pharmacokinetic Study Evaluating Ra101495 Sc In Patients With Renal Impairment

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 1B PHARMACOKINETIC STUDY EVALUATING RA101495 SC IN PATIENTS WITH RENAL IMPAIRMENT Source text for Eikon: Further company coverage:

BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC

* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS

BRIEF-Ra Pharmaceuticals Announces Positive Interim Results From Phase 2 Study Of RA101495 SC

* RA PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF RA101495 SC IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA

BRIEF-Ra Pharmaceuticals posts Q3 loss of $0.68 per share

* Ra pharmaceuticals reports third quarter 2017 financial results and provides corporate update

BRIEF-Ra Pharmaceuticals files for mixed shelf offering of up to $250 million

* Ra Pharmaceuticals Inc files for mixed shelf offering of up to $250 million - SEC filing Source text: (http://bit.ly/2A6uuro) Further company coverage:

BRIEF-Ra Pharmaceuticals reports Q2 loss per share $0.56

* Ra Pharmaceuticals reports second quarter 2017 financial results and provides corporate update

BRIEF-RA Pharmaceuticals receives orphan drug designation from FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

* RA Pharmaceuticals receives orphan drug designation from the U.S. FDA for RA101495 for the treatment of paroxysmal nocturnal hemoglobinuria

BRIEF-Ra Pharmaceuticals announces data from phase 2 clinical trial of RA101495

* Ra Pharmaceuticals announces initial data from phase 2 clinical trial of RA101495 in Pnh

BRIEF-RA Pharmaceuticals Q1 loss per share $0.50

* RA Pharmaceuticals reports first quarter 2017 financial results and provides corporate update

BRIEF-RA Pharmaceuticals Q4 loss per share $0.74

* RA Pharmaceuticals reports fourth quarter and full year 2016 financial results and provides corporate update

BRIEF-Lightstone Ventures LP reports 5.9 pct passive stake in Ra Pharmaceuticals Inc as on Dec 31, 2016

* Lightstone Ventures L.P. reports 5.9 percent passive stake in ra pharmaceuticals inc as on December 31, 2016 - SEC filing Source text (http://bit.ly/2knlOsD) Further company coverage:

BRIEF-Ra Pharmaceuticals reports Q3 loss per share $14.22

* Ra Pharmaceuticals reports third quarter 2016 financial results and provides corporate update

BRIEF-Ra Pharmaceuticals receives orphan drug designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria

* Ra Pharmaceuticals receives orphan drug designation in the European Union for RA101495 for Treatment of Paroxysmal Nocturnal Hemoglobinuria Source text for Eikon: Further company coverage:

BRIEF-RA Capital Management reports 6.3 pct stake in RA Pharmaceuticals

Ra Capital Management Reports 6.3 Pct Stake In Ra Pharmaceuticals Inc

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up